R&G PharmaStudies Co. Ltd. A (301333) — Capital Reinvestment Ratio
R&G PharmaStudies Co. Ltd. A (301333) has a Capital Reinvestment Ratio of 0.13x as of June 2022, meaning it reinvests 0% of its operating cash flow (CN¥40.98 Million) in capital expenditures (CN¥5.24 Million). See 301333 net asset quality index to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
R&G PharmaStudies Co. Ltd. A Capital Reinvestment Ratio (2019–2025)
This chart tracks R&G PharmaStudies Co. Ltd. A's Capital Reinvestment Ratio across 7 annual periods. Check 301333 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year Capital Reinvestment Ratio for R&G PharmaStudies Co. Ltd. A from 2019 to 2025. For live market cap and broader valuation context, see 301333 company net worth.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.17x | CN¥114.20 Million | CN¥19.28 Million | ▲ +30.7% |
| 2024 | 0.13x | CN¥154.76 Million | CN¥19.98 Million | ▲ +25.1% |
| 2023 | 0.10x | CN¥192.56 Million | CN¥19.88 Million | ▼ -35.3% |
| 2022 | 0.16x | CN¥130.47 Million | CN¥20.83 Million | ▼ -52.2% |
| 2021 | 0.33x | CN¥114.57 Million | CN¥38.28 Million | ▼ -42.2% |
| 2020 | 0.58x | CN¥44.10 Million | CN¥25.48 Million | ▲ +129.9% |
| 2019 | 0.25x | CN¥103.48 Million | CN¥26.00 Million | — |